Insta
With Three Drugmakers In Final Stages Of Testing, US Preparing For Distribution Of Covid-19 Vaccine By 1 November
Swarajya Staff
Sep 03, 2020, 02:22 PM | Updated 02:22 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
With three pharma companies carrying final stage trials of the Covid-19 vaccine in the United States, the Trump administration has begun the preparation for the mass distribution of the vaccine.
The US states has been urged by the Trump administration to get ready to distribute a potential Covid-19 vaccine by 1 November - two days ahead of the 2020 US Presidential election, reports Times of India.
According to the report, McKesson Corp, a Dallas-based wholesaler, has a deal with the federal government and will be seeking permits to establish distribution centres when a vaccine becomes available.
In a letter to the US states on 27 August, the director of the US Centre for Disease Control and Prevention, Robert Redfield urged the states to assist in expediting distribution facilities' applications.
"The normal time required to obtain these permits presents a significant barrier to the success of this urgent public health program," Redfield was quoted as saying in the letter.
"CDC urgently requests your assistance in expediting applications for these distribution facilities," he said.
Redfield also urged the states to consider waiving requirements that would "prevent these facilities from becoming fully operational by Nov. 1, 2020."
The states have also been provided with documents by the CDC, giving the details of a vaccine rollout plan, adding that they would either be approved as licensed vaccines or under emergency use authorisation.
As per the documents, the recipient may probably require a second "booster" dose, a few weeks after the first dose.
Three pharma companies - AstraZeneca in partnership with the Oxford University; Moderna, collaborating with the US National Institutes of Health; and the Pfizer/BioNTech alliance - have been conducting the Phase 3 clinical trials of their Covid-19 vaccines, involving thousands of volunteers.
The federal government will be procuring and distributing the vaccine and ancillary supplies at no cost to enrolled Covid-19 vaccination providers, according to the documents.
As per the report, the essential service workers, national security officials, seniors and members of vulnerable racial and ethnic groups will be given priority in the Covid-19 vaccination programme.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.